Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents

Fabio Colella, João Pedro Garcia, Marco Sorbona, Andrea Lolli, Bernardo Antunes, Domenico D'Atri, Florian P.Y. Barré, Jacopo Oieni, Maria Letizia Vainieri, Luana Zerrillo, Serdar Capar, Sonja Häckel, Yunpeng Cai, Laura B. Creemers*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

35 Citations (Scopus)
35 Downloads (Pure)

Abstract

Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.

Original languageEnglish
Pages (from-to)985-999
Number of pages15
JournalJournal of Controlled Release
Volume328
Early online date27 Aug 2020
DOIs
Publication statusPublished - 10 Dec 2020

Bibliographical note

Acknowledgement

We would like to acknowledge Prof. Gerjo Van Osch and prof Molly Stevens for their careful and critical revision of the manuscript. We wish to thank all principal investigators of the TargetCaRe consortium for their enormous support during the years: Prof G. van Osch. Prof. Mauro Alini, Prof. Bruce Caterson, Dr. Alan Chan, Prof. Cosimo De Bari, Prof. Ron Heeren, Prof. Kennet Howard, Prof. Marcelle Machluf, Prof. Molly M. Stevens and Prof. Avner Yayon.

This work was supported by European Union's Horizon 2020 Research And Innovation Programme under Marie Sklodowska Curie Grant agreement no. 642414.

Fingerprint

Dive into the research topics of 'Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents'. Together they form a unique fingerprint.

Cite this